| Autor: |
Fozia Zahir Ahmed, Camilla Sammut‐Powell, Glen P. Martin, Paul Callan, Colin Cunnington, Matthew Kahn, Mita Kale, Toni Weldon, Rachel Harwood, Catherine Fullwood, Bart Gerritse, David Lanctin, Nelson Soken, Niall G. Campbell, Joanne K. Taylor |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
ESC Heart Failure, Vol 11, Iss 5, Pp 2637-2647 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2055-5822 |
| DOI: |
10.1002/ehf2.14821 |
| Popis: |
Abstract Aims Clinical pathways have been shown to improve outcomes in patients with heart failure (HF). Although patients with HF often have a cardiac implantable electronic device, few studies have reported the utility of device‐derived risk scores to augment and organize care. TriageHF Plus is a device‐based HF clinical pathway (DHFP) that uses remote monitoring alerts to trigger structured telephone assessment for HF stability and optimization. We aimed to evaluate the impact of TriageHF Plus on hospitalizations and describe the associated workforce burden. Methods and results TriageHF Plus was a multi‐site, prospective study that compared outcomes for patients recruited between April 2019 and February 2021. All alert‐triggered assessments were analysed to determine the appropriateness of the alert and the workload burden. A negative‐binomial regression with inverse probability treatment weighting using a time‐matched usual care cohort was applied to estimate the effect of TriageHF Plus on non‐elective hospitalizations. A post hoc pre‐COVID‐19 sensitivity analysis was also performed. The TriageHF Plus cohort (n = 443) had a mean age of 68.8 ± 11.2 years, 77% male (usual care cohort: n = 315, mean age of 66.2 ± 14.5 years, 65% male). In the TriageHF Plus cohort, an acute medical issue was identified following an alert in 79/182 (43%) cases. Fifty assessments indicated acute HF, requiring clinical action in 44 cases. At 30 day follow‐up, 39/66 (59%) of initially symptomatic patients reported improvement, and 20 (19%) initially asymptomatic patients had developed new symptoms. On average, each assessment took 10 min. The TriageHF Plus group had a 58% lower rate of hospitalizations across full follow‐up [incidence relative ratio: 0.42, 95% confidence interval (CI): 0.23–0.76, P = 0.004]. Across the pre‐COVID‐19 window, hospitalizations were 31% lower (0.69, 95% CI: 0.46–1.04, P = 0.077). Conclusions These data represent the largest real‐world evaluation of a DHFP based on multi‐parametric risk stratification. The TriageHF Plus clinical pathway was associated with an improvement in HF symptoms and reduced all‐cause hospitalizations. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text